Dompé sells six brands to Substipharm

25 November 2021

Privately-held Italian biopharma company Dompé Farmaceutici has announced the sale of six brands to French drugmaker Substipharm, which specializes in niche generic and mature pharmaceutical products.

The brands involved in the agreement are: Eparmefolin (antiemetic), Citofolin (calcium folinate supplement), Luminale (general sedative), Memac (acetylcholinesterase inhibitor), Rigentex (vitamin E), Broncomnes (mucus regulator). Financial terms of the transaction were not disclosed.

"Our objective is to strengthen our commitment to strategic areas and brands for Italy and continue the geographical expansion project for Primary Care," says Davide Polimeni, chief commercial officer Primary Care of Dompé Pharmaceuticals, adding: "This operation on the Italian market is part of a focused path that will see us increasingly committed to enhancing corporate assets in a critical investment and development program for our key brands, in line with our five years strategic plan."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK